Anders Romare, Chief Digital and Information Officer and SVP of Global Data, and IT at Novo Nordisk, speaks with Lana Feng, Co-founder and CEO of Huma.Ai, in a video interview about the impact of Generative AI (GenAI) on the pharma industry, its wide range of use cases, and the impact on jobs.
Novo Nordisk is a multinational pharmaceutical company headquartered in Bagsværd, Denmark.
Sharing his views on how generative AI could impact the pharma industry, Romare says that while GenAI has a wide range of use cases, it has made it possible to put AI technology in the hands of a larger section of employees.
This further opens up uses like the following:
Knowledge workers creating marketing campaigns, summarizing information, and writing assets like presentations
Speeding up consumption of information, like getting a summary of a two-hour-long meeting in five minutes
Driving efficiency in developing and testing software
Moving from ideas to target validation faster in the drug discovery phase
Sorting, understanding, and digesting enormous amounts of data from clinical trials
Summarizing data for submission to authorities
Targeting patients, doctors, and healthcare professionals better with value propositions
Adding digital and data components to the drug components to provide a holistic offer to patients
When asked about the impact of GenAI on jobs, Romare says that historically, any technology shift has led to the continued evolution of mankind. It typically leads to gaining efficiency, which can be invested in other areas.
He adds that freeing up capacity in a field like pharma can lead to more innovation capacity to discover more medicine and drive it to the market stage. There will be a lot of opportunities to continue to develop and deliver value to patients, Romare concludes.
CDO Magazine appreciates Anders Romare for sharing his insights and data success stories with our global community.